Skip to main content

Advertisement

SpringerLink
Log in

Azithromycin: Single 1.5g dose in the treatment of patients with atypical pneumonia syndrome—A randomized study

  • Originalia
  • Published:
Infection Aims and scope Submit manuscript

Summary

An open comparative study was undertaken in order to assess the efficacy and safety of a single dose of azithromycin in the treatment of community-acquired atypical pneumonia. A total of 100 adult patients with atypical penumonia syndrome were randomized to receive 1.5 g of azithromycin as a single dose, or 500 mg once daily for 3 days. The presence ofMycoplasma pneumoniae, Chlamydia pneumoniae, Chlamydia psittaci, Coxiella burnetii, andLegionella pneumophila infection was diagnosed by serological tests. Control clinical examinations were performed 72h, 10–12 days and 4 weeks after treatment initiation. Among 96 patients (48 in each group) who were evaluable for clinical efficacyM. pneumoniae infection was confirmed in 24,C. pneumoniae in nine,C. psittaci in five,C. burnetii in six, andL. pneumophila in five. Forty-seven patients (97.9%) in each group were cured. Side effects were observed in two patients in the single-dose group, and one patient in the 3-day group. In conclusion, a single 1.5 g dose of azithromycin may be an alternative to the standard 3-day azithromycin regimen in the treatment of outpatients with atypical pneumonia syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Levison, M. E.: Pneumonia, including necrotizing pulmonary infections (lung abscess). In:Isselbacher, K. J., Braunwald, E., Wilson, J. D., Martin, J. B., Fauci, A. S., Kasper, D. L. (eds.) Harrison's principles of internal medicine. McGraw-Hill, New York 1994, pp. 1184–1191.

    Google Scholar 

  2. Donowitz, G. R., Mandell, G. L.: Acute pneumonia. In:Mandell, G. L., Bennett, J. E., Dolin, R. (eds.), Mandell, Douglas and Bennett's principles and practice of infectious diseases. Churchill Livingstone, New York 1995, pp. 619–637.

    Google Scholar 

  3. Cunha, B. A., Ortega, A. M.: Atypical pneumonia Extrapulmonary clues guide the way to diagnosis. Postgrad. Med. 99 (1996) 123–132.

    PubMed  CAS  Google Scholar 

  4. Hoepelman, I. M., Schneider, M. M. E.: Azithromycin: the first of the tissue-selective azalides. Int. J. Antimicrob. Agents 5 (1995) 145–167.

    Article  CAS  PubMed  Google Scholar 

  5. Renaudin, H., Bebear, C.: Comparativein vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin againstMycoplasma pneumoniae, Mycoplasma hominis andUreaplasma urealyticum. Eur. J. Clin. Microbiol. Infect. Dis. 9 (1990) 838–841.

    Article  PubMed  CAS  Google Scholar 

  6. Felmingham, D., Robbins, M. J., Sanghrajka, M., Leakey, A., Ridgway, G. L.: Thein vitro activity of some 14-, 15- and 16-membered macrolides againstStaphylococcus spp.,Legionella spp.,Mycoplasma spp. andUreaplasma urealyticum. Drugs Exp. Clin. Res. 17 (1991) 91–99.

    PubMed  CAS  Google Scholar 

  7. Ishida, K., Kaku, M., Irifune, K., Mizukane, R., Takemura, H., Yoshida, R., Tanaka, H., Usui, T., Suyama, N., Tomono, K., Koga, H., Kohno, S., Izumikawa, K., Hara, K.:In vitro andin vivo activities of macrolides againstMycoplasma pneumoniae. Antimicrob. Agents Chemother. 38 (1994) 790–798.

    PubMed  CAS  Google Scholar 

  8. Niki, Y., Kimura, M., Miyashita, N., Soejima, R.:In vitro andin vivo activities of azithromycin, a new azalide antibiotic, against chlamydia. Antimicrob. Agents Chemother. 38 (1994) 2296–2299.

    PubMed  CAS  Google Scholar 

  9. Hammerschlag, M. R.: Antimicrobial susceptibility and therapy of infections caused byChlamydia pneumoniae. Antimicrob. Agents Chemother. 38 (1994) 1873–1878.

    PubMed  CAS  Google Scholar 

  10. Welsh, L., Gaydos, C., Quinn, T. C.:In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains ofChlamydia pneumoniae. Antimicrob. Agents Chemother. 40 (1996) 212–214.

    PubMed  CAS  Google Scholar 

  11. Barry, A. L., Jones, R. N., Thornsberry, C.:In vitro activities of azithromycin (CP-62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. Antimicrob. Agents Chemother. 32 (1988) 752–754.

    PubMed  CAS  Google Scholar 

  12. Johnson, D. M., Erwin, M. E., Barrett, M. S., Briggs Gooding, B., Jones, R. N.: Antimicrobial activity of ten macrolide, lincosamine and streptogramin drugs tested againstLegionella species. Eur. J. Clin. Microbiol. Infect. Dis. 11 (1992) 751–755.

    Article  PubMed  CAS  Google Scholar 

  13. Nimmo, G. R., Bull, J. Z.: Comparative susceptibility ofLegionella pneumophila andLegionella longbacheae to 12 antimicrobial agents. J. Antimicrob. Chemother. 36 (1995) 219–223.

    Article  PubMed  CAS  Google Scholar 

  14. Keysary, A., Itzhaki, A., Rubinstein, E., Oron, C., Keren, G.: Thein vitro anti-rickettsial activity of macrolides. J. Antimicrob. Chemother. 38 (1996) 727–731.

    Article  PubMed  CAS  Google Scholar 

  15. Foulds, G., Shepard, R. M., Johnson, R. B.: The pharmacokinetics of azithromycin in human serum and tissues J. Antimicrob. Chemother. 25 (Suppl. A) (1990) 73–82.

    PubMed  CAS  Google Scholar 

  16. Morris, D. L., De Souza, A., Jones, J. A., Morgan, W. E.: High and prolonged pulmonary tissue concentrations of azithromycin following a single oral dose. Eur. J. Clin. Microbiol. Infect. Dis. 10 (1991) 859–861.

    Article  PubMed  CAS  Google Scholar 

  17. Baldwin, D. R., Wise, R., Andrews, J. M., Ashby, J. P., Honeybourne, D.: Azithromycin concentrations at the sites of pulmonary infection. Eur. Respir. J. 3 (1990) 886–890.

    PubMed  CAS  Google Scholar 

  18. Schönwald, S., Gunjača, M., Kolačny-Babić, L., Car, V., Gošev, M.: Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. J. Antimicrob. Chemother. 25 (Suppl. A) (1990) 123–126.

    PubMed  Google Scholar 

  19. Schönwald, S., Škerk, V., Petričević, I., Car, V., Majerus-Mišić, Lj., Gunjača, M.: Comparison of three-day and five-day courses of azithromycin in the treatment of atypical pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 10 (1991) 877–880.

    Article  PubMed  Google Scholar 

  20. Schönwald, S., Baršić, B., Klinar, I., Gunjača, M.: Three-day azithromycin compared with ten-day roxithromycin treatment of atypical pneumonia. Scand. J. Infect. Dis. 26 (1994) 706–710.

    Article  PubMed  Google Scholar 

  21. Kuzman, I., Schönwald, S., Čulig, J., Orešković, K.: Azithromycin, erythromycin and doxycycline in the treatment ofMycoplasma pneumoniae pneumonia: a retrospective study. In:Berkarda, B. (ed.). 10th Mediterranean Congress of Chemotherapy. Monduzzi Editore. Bologna 1996, pp. 211–214.

    Google Scholar 

  22. Kuzman, I., Orešković, K., Schönwald, S., Čulig, J.: Azithromycin in treatment of pneumonias caused byChlamydia spp.: a retrospective study. Int. J. Clin. Pharm. Res. 16 (1997) 103–107.

    Google Scholar 

  23. Kuzman, I., Soldo, I., Schönwald, S., Čulig, J.: Azithromycin for treatment of community-acquired pneumonia caused byLegionella pneumophila: a retrospective study. Scand. J. Infect. Dis. 27 (1995) 503–505.

    PubMed  CAS  Google Scholar 

  24. Bohte, R., van't Wout, J.W., Lobatto, S., Blussé van Oud Alblas A., Boekhout, M., Nauta, E. H., Hermans, J., van den Broek, P. J.: Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 14 (1995) 182–187.

    Article  PubMed  CAS  Google Scholar 

  25. Sočan, M.: Treatment of atypical pneumonia with azithromycin: comparison of a 5-day and a 3-day course. J. Chemother. 10 (1998) 64–68.

    PubMed  Google Scholar 

  26. Kuzman, I.: Community-acquired pneumonia: etiologic diagnosis and strategy of antibiotic therapy (doctoral thesis). Zagreb University, Zagreb 1994.

    Google Scholar 

  27. Tartakovskii, I. S., Sinopalnikov, A. J., Martinova, V. R., Gorina, L. G., Komissarov, A. L., Rakov, A. J., Prosorovskii, S. V.: Communityacquired pneumonia: etiologic diagnosis and strategy of antibiotic therapy. In: Legionella infections and atypical pneumonias. Proceedings of the 11th meeting of the European Working Group on Legionella Infections. Oslo, Norway, 2–4 June 1996. The Norwegian Defence Microbiological Laboratory, Joint Medical Services, HQ Defense Command Norway, Oslo 1996, pp. 149–152.

    Google Scholar 

  28. The Nordic Atypical Pneumonia Study Group: Atypical pneumonia in the Nordic countries: aetiology and clinical results of a trial comparing fleroxacin and doxycycline. J. Antimicrob. Chemother. 39 (1997) 499–508.

    Article  Google Scholar 

  29. Lieberman, D., Ben-Yaakov, M., Lazarovich, Z., Porath, A., Schaeffer, F., Lieberman, D., Leinonen, M., Saikku, P., Horovitz, O., Boldur, I.: Chlamydia pneumoniae community-acquired pneumonia: a review of 62 hospitalized adult patients Infection 24 (1996) 109–114.

    Article  PubMed  CAS  Google Scholar 

  30. Baum S. G.: Mycoplasma pneumoniae and atypical pneumonia. In:Mandell, G. L., Bennett, J. E., Dolin, R. (eds.): Mandell, Douglas and Bennett's principles and practice of infectious diseases. Churchill Livingstone. New York 1995, pp. 1704–1713.

    Google Scholar 

  31. Grayston, T. J.: Chlamydia pneumoniae (TWAR). In:Mandell, G. L., Bennett, J. E., Dolin R. (eds.). Mandell, Douglas and Bennett's principles and practice of infectious diseases. Churchill Livingstone. New York 1995, pp. 1696–1701.

    Google Scholar 

  32. Stout, J. E., Yu, V. L.: Legionellosis. N. Engl. J. Med. 337 (1997) 682–687.

    Article  PubMed  CAS  Google Scholar 

  33. Marrie, T. J.:Coxiella burnetii (Q fever). In:Mandell, G. L., Bennett, J. E., Dolin, R. (eds.): Mandell, Douglas and Bennett's principles and practice of infectious diseases. Churchill Livingstone. New York 1995, pp. 1727–1735.

    Google Scholar 

  34. Fitzgeorge, R. B., Featherstone, A. S. R., Baskerville, A.: Efficacy of azithromycin in the treatment of guinea pigs infected with,Legionella pneumophila by aerosol. J. Antimicrob. Chemother. 25 (Suppl. A) (1990) 101–108.

    PubMed  CAS  Google Scholar 

  35. Fitzgeorge, R. B., Lever, S., Baskerville, A.: A comparison of the efficacy of azithromycin and clarithromycin in oral therapy of experimental airborne legionnaires' disease. J. Antimicrob. Chemother. 31 (Suppl. E) (1993) 171–176.

    PubMed  Google Scholar 

  36. Malinverni, R., Kuo, C. C., Campbell, L. A., Lee, A., Grayston, J. T.: Effects of two antibiotic regimens on course and persistence of experimentalChlamydia pneumoniae TWAR pneumonitis. Antimicrob. Agents Chemother. 39 (1995) 45–49.

    PubMed  CAS  Google Scholar 

  37. Cunha, B. A.: The antibiotic treatment of community-acquired, atypical, and nosocomial pneumonias. Med. Clin. North Am. 79 (1995) 581–597.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Hospital of Infectious Diseases “Dr. Fran Mihaljevic”, Mirogøjska cesta 8, HR-10000, Zagreb, Croatia

    S. Schönwald M.D., Ph. D., I. Kuzman M. D., Ph. D., V. Burek M. D., Ph. D., V. Škerk M. D., Ph. D., V. Car M. D. & D. Božinović M. D., Ph. D.

  2. Plivad.d. Pharmaceuticals Div., Ulica grada Vukovara 49, HR-10000, Zagreb, Croatia

    K. Orešković M. D., Ph. D., J. Čulig M. D., M. Sc. & S. Radošević B. Math., M. Sc.

Authors
  1. S. Schönwald M.D., Ph. D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. Kuzman M. D., Ph. D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Orešković M. D., Ph. D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V. Burek M. D., Ph. D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V. Škerk M. D., Ph. D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. V. Car M. D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D. Božinović M. D., Ph. D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. Čulig M. D., M. Sc.
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S. Radošević B. Math., M. Sc.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schönwald, S., Kuzman, I., Orešković, K. et al. Azithromycin: Single 1.5g dose in the treatment of patients with atypical pneumonia syndrome—A randomized study. Infection 27, 198–202 (1999). https://doi.org/10.1007/BF02561528

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02561528

Keywords

Search

Navigation